INT80037

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.75
First Reported 1999
Last Reported 2010
Negated 1
Speculated 1
Reported most in Body
Documents 58
Total Number 59
Disease Relevance 39.49
Pain Relevance 9.08

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

cytosol (BAK1) mitochondrion (BAK1) aging (BAK1)
endoplasmic reticulum (BAK1) intracellular (BAK1)
Anatomy Link Frequency
pancreas 1
nucleus 1
apoptotic cells 1
dorsal horn 1
ducts 1
BAK1 (Homo sapiens)
Pain Link Frequency Relevance Heat
cINOD 95 99.98 Very High Very High Very High
Dismenorea 2 99.96 Very High Very High Very High
Inflammation 393 99.68 Very High Very High Very High
Neuropathic pain 2 99.68 Very High Very High Very High
dexamethasone 10 98.72 Very High Very High Very High
Glutamate 2 98.66 Very High Very High Very High
Dorsal horn 1 98.56 Very High Very High Very High
Chronic pancreatitis 2 98.12 Very High Very High Very High
Inflammatory response 15 97.28 Very High Very High Very High
Sciatic nerve 1 96.84 Very High Very High Very High
Disease Link Frequency Relevance Heat
Apoptosis 1084 100.00 Very High Very High Very High
Toxicity 219 100.00 Very High Very High Very High
Dysmenorrhea 2 99.96 Very High Very High Very High
INFLAMMATION 521 99.86 Very High Very High Very High
Disease 414 99.70 Very High Very High Very High
Neuropathic Pain 2 99.68 Very High Very High Very High
Fever 41 99.60 Very High Very High Very High
Lung Cancer 433 99.58 Very High Very High Very High
Disorder Of Lipid Metabolism 3 99.56 Very High Very High Very High
Adenocarcinoma 22 99.08 Very High Very High Very High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Detailed tissue expression of bcl-2, bax, bak and bcl-x in the normal human pancreas and in chronic pancreatitis, ampullary and pancreatic ductal adenocarcinomas.
Gene_expression (expression) of bak in pancreas associated with adenocarcinoma and chronic pancreatitis
1) Confidence 0.75 Published 2001 Journal Pancreatology Section Title Doc Link 12120204 Disease Relevance 0.19 Pain Relevance 0.10
BAK remains mostly in the lipophilic phase when prepared as an emulsion solution.74 Only 1.2% of BAK is the free and actively toxic preservative.75 Studies have shown that emulsions of BAK preservative reduce its detrimental effects, but they do not eliminate them.76
Gene_expression (emulsion) of BAK
2) Confidence 0.66 Published 2010 Journal Clinical Ophthalmology (Auckland, N.Z.) Section Body Doc Link PMC2921296 Disease Relevance 0.36 Pain Relevance 0.03
Though this study importantly demonstrates no significant differences in comfort between BAK-free travoprost and latanoprost preserved with BAK, the data collected were after only 1 dose.
Gene_expression (travoprost) of BAK-free
3) Confidence 0.66 Published 2010 Journal Clinical Ophthalmology (Auckland, N.Z.) Section Body Doc Link PMC2921296 Disease Relevance 0.14 Pain Relevance 0.12
Perhaps a longer time period will illicit a difference in patients’ comfort between travoprost preserved with BAK and Travatan Z.
Gene_expression (preserved) of BAK
4) Confidence 0.66 Published 2010 Journal Clinical Ophthalmology (Auckland, N.Z.) Section Body Doc Link PMC2921296 Disease Relevance 0.45 Pain Relevance 0.07
Baudouin et al (2007) investigated, in
               vitro, prostaglandin solutions preserved with BAK and the BAK-free solution
               travoprost Z 0.004%, evaluating their effects on cellular viability,
               membrane integrity, and apoptosis through microtitration fluorometric assays and
               flow cytometry. 
Gene_expression (preserved) of BAK associated with apoptosis
5) Confidence 0.64 Published 2008 Journal Clinical Ophthalmology (Auckland, N.Z.) Section Body Doc Link PMC2699817 Disease Relevance 0.53 Pain Relevance 0.07
Expression levels of Bak and Bax, and the activation of caspases 3 and 7 in HUVECs significantly increased when treated with morphine.
Gene_expression (levels) of Bak associated with morphine
6) Confidence 0.64 Published 2009 Journal Toxicology Section Abstract Doc Link 19070643 Disease Relevance 0.58 Pain Relevance 0.95
Within the kits, all medications (whether BAK-preserved latanoprost 0.005% or BAK-free travoprost 0.004%) were packaged in identical oval 4 mL polypropylene dropper bottles.
Gene_expression (travoprost) of BAK-preserved
7) Confidence 0.59 Published 2010 Journal Clinical Ophthalmology (Auckland, N.Z.) Section Body Doc Link PMC2993125 Disease Relevance 0.08 Pain Relevance 0
11.3 ± 17.2 for the 339 patients in the BAK-free travoprost 0.004% group and ?
Gene_expression (travoprost) of BAK-free
8) Confidence 0.59 Published 2010 Journal Clinical Ophthalmology (Auckland, N.Z.) Section Body Doc Link PMC2993125 Disease Relevance 0.14 Pain Relevance 0
The IOP-lowering efficacy is equivalent between BAK-free travoprost 0.004% and BAK-preserved travoprost 0.004%.27 Therefore, physicians could reasonably consider a switch from a BAK-preserved therapy to BAK-free travoprost 0.004% in patients with ongoing glaucoma who have comorbid OSD, or could consider initiating BAK- free travoprost 0.004% in new glaucoma patients who are at risk of developing OSD due to use of BAK-preserved products.
Gene_expression (products) of BAK-preserved associated with glaucoma, disease and ocular hypertension
9) Confidence 0.59 Published 2010 Journal Clinical Ophthalmology (Auckland, N.Z.) Section Body Doc Link PMC2993125 Disease Relevance 1.26 Pain Relevance 0
5.0 ± 10.8 units, n = 140) than for patients with mild OSD at baseline who continued on BAK-preserved latanoprost 0.005% (?
Gene_expression (latanoprost) of BAK-preserved associated with disease
10) Confidence 0.59 Published 2010 Journal Clinical Ophthalmology (Auckland, N.Z.) Section Body Doc Link PMC2993125 Disease Relevance 0.26 Pain Relevance 0
Within the kits, all medications (whether BAK-preserved latanoprost 0.005% or BAK-free travoprost 0.004%) were packaged in identical oval 4 mL polypropylene dropper bottles.
Gene_expression (travoprost) of BAK-free
11) Confidence 0.59 Published 2010 Journal Clinical Ophthalmology (Auckland, N.Z.) Section Body Doc Link PMC2993125 Disease Relevance 0.08 Pain Relevance 0
In pancreatic ductal adenocarcinoma and ampullary cancer, bcl-2 was not detected compared with expression seen in normal acini (p < 0.01), minor (p < 0.001) and major ducts (p < 0.01), bax expression was reduced with respect to minor ducts (p < 0.01) but no different from normal acini or major ducts. bak and bcl-x were more strongly expressed in malignant epithelia compared with acini and major ducts but reduced when compared with minor ducts (p < 0.01).
Gene_expression (expressed) of bak in ducts
12) Confidence 0.58 Published 2001 Journal Pancreatology Section Body Doc Link 12120204 Disease Relevance 0.06 Pain Relevance 0
Though this study importantly demonstrates no significant differences in comfort between BAK-free travoprost and latanoprost preserved with BAK, the data collected were after only 1 dose.
Gene_expression (preserved) of BAK
13) Confidence 0.58 Published 2010 Journal Clinical Ophthalmology (Auckland, N.Z.) Section Body Doc Link PMC2921296 Disease Relevance 0.09 Pain Relevance 0.12
Attrition rates due to treatment-related side effects were recorded to be 1.5% in travoprost BAK-free and 1.2% in travoprost 0.004% BAK.88
Gene_expression (travoprost) of BAK
14) Confidence 0.58 Published 2010 Journal Clinical Ophthalmology (Auckland, N.Z.) Section Body Doc Link PMC2921296 Disease Relevance 0.45 Pain Relevance 0.11
Travoprost BAK-free solution (Travatan Z®; Alcon Laboratories, Inc, Fort Worth, Texas, USA) is the first PG analogue without BAK preservative made for commercial use.
Gene_expression (solution) of BAK-free
15) Confidence 0.58 Published 2010 Journal Clinical Ophthalmology (Auckland, N.Z.) Section Body Doc Link PMC2921296 Disease Relevance 0.44 Pain Relevance 0.04
BAK remains mostly in the lipophilic phase when prepared as an emulsion solution.74 Only 1.2% of BAK is the free and actively toxic preservative.75 Studies have shown that emulsions of BAK preservative reduce its detrimental effects, but they do not eliminate them.76
Gene_expression (emulsions) of BAK
16) Confidence 0.58 Published 2010 Journal Clinical Ophthalmology (Auckland, N.Z.) Section Body Doc Link PMC2921296 Disease Relevance 0.25 Pain Relevance 0.03
Attrition rates due to treatment-related side effects were recorded to be 1.5% in travoprost BAK-free and 1.2% in travoprost 0.004% BAK.88
Gene_expression (travoprost) of BAK-free
17) Confidence 0.58 Published 2010 Journal Clinical Ophthalmology (Auckland, N.Z.) Section Body Doc Link PMC2921296 Disease Relevance 0.45 Pain Relevance 0.10
Efficacy and patient tolerability of travoprost BAK-free solution in patients with open-angle glaucoma and ocular hypertension

The medical treatment of glaucoma has evolved significantly over the past several decades.

Gene_expression (solution) of BAK-free associated with glaucoma and ocular hypertension
18) Confidence 0.58 Published 2010 Journal Clinical Ophthalmology (Auckland, N.Z.) Section Title Doc Link PMC2921296 Disease Relevance 0.88 Pain Relevance 0.14
Another prospective explanation cited by the authors included the potential for BAK and the PG analogues forming an emulsion, thus reducing the BAK exposure.
Gene_expression (exposure) of BAK
19) Confidence 0.58 Published 2010 Journal Clinical Ophthalmology (Auckland, N.Z.) Section Body Doc Link PMC2921296 Disease Relevance 0.61 Pain Relevance 0.06
Within this study, treatment-related ocular hyperemia was reported 9.0% of the time among those using travoprost preserved with 0.004% BAK and 6.4% of the time among those using BAK-free travoprost, but these data were not statistically significant.
Gene_expression (travoprost) of BAK-free associated with increased venous pressure under development
20) Confidence 0.58 Published 2010 Journal Clinical Ophthalmology (Auckland, N.Z.) Section Body Doc Link PMC2921296 Disease Relevance 0.57 Pain Relevance 0.04

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox